• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Provider Acceptance Driving Confidence in Biosimilar Therapy


Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asked Abraham about the role of provider acceptance and confidence in biosimilars in driving adoption for inflammatory conditions.

Abraham said if a payer requires switching to a biosimilar, providers must comply regardless of confidence. However, provider knowledge of the biosimilar’s efficacy, safety, expected effects of switching, and so on allows confident counseling of patients concerned about changes in their medication for chronic disease. An informed provider can explain details to patients, reducing nocebo effects from anxiety about switching. Provider knowledge and confidence in biosimilars significantly helps adoption from the provider and patient standpoint.

Haumschild agreed that provider understanding of data enables confident prescribing and trust from patients, which has been crucial for biosimilar adoption. This transition of acceptance and confidence will be vital as inflammatory disease options expand.

Video synopsis is AI-generated and reviewed by editorial staff.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.